<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374931</url>
  </required_header>
  <id_info>
    <org_study_id>VICC SAR 1458</org_study_id>
    <secondary_id>NCI-2015-00081</secondary_id>
    <secondary_id>VICC SAR 1458</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02374931</nct_id>
  </id_info>
  <brief_title>18F-FES PET/CT in Imaging Patients With Desmoid Tumors</brief_title>
  <official_title>Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron
      emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors.
      18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off
      radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may
      show where tumor cells with estrogen receptors can be found in the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES
      PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC).

      OUTLINE:

      Patients undergo 18F-FES PET/CT imaging over 30 minutes.

      After completion of study, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard uptake value (SUV) measured as percent injected dose per cc</measure>
    <time_frame>Initial visit, average within 24 hours of imaging</time_frame>
    <description>Data will be summarized graphically and numerically. Continuous variables (e.g. SUV) will be summarized using the mean, standard deviation, and a 5 number percentile summary set (minimum, p25, p50, p75, and maximum). The Spearman correlation statistic will be used to estimate the magnitude of a linear association between SUV and IHC measures. Ninety-five percent confidence intervals will be calculated for all point estimates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IHC staining intensity in tissue samples</measure>
    <time_frame>Within 4 weeks of imaging done at initial visit, day 1</time_frame>
    <description>IHC staining intensity measured on an ordinal scale or dichotomized as positive or negative. Data will be summarized graphically and numerically. Categorical measures (e.g., IHC) will be summarized in frequency tables. The Spearman correlation statistic will be used to estimate the magnitude of a linear association between SUV and IHC measures. Ninety-five percent confidence intervals will be calculated for all point estimates.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Deep Fibromatosis/Desmoid Tumor</condition>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F-FES PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 18F-FES PET/CT imaging over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 16 Alpha-Fluoroestradiol</intervention_name>
    <description>Undergo 18F-FES PET/CT</description>
    <arm_group_label>Diagnostic (18F-FES PET/CT)</arm_group_label>
    <other_name>16 alpha-fluroestradiol-17 beta</other_name>
    <other_name>F-18 FES</other_name>
    <other_name>FES</other_name>
    <other_name>Fluorine-18 16 alpha-fluoroestradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-FES PET/CT</description>
    <arm_group_label>Diagnostic (18F-FES PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo 18F-FES PET/CT</description>
    <arm_group_label>Diagnostic (18F-FES PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (18F-FES PET/CT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biopsy-proven extra-abdominal desmoid tumors

          -  Not currently on estrogen medication for birth control, menopause, or other reason

          -  No anti-estrogen therapy for desmoid tumor within the past 6 months

          -  Both sporadic desmoid tumors and those associated with familial adenomatous polyposis
             (FAP) syndromes will be included

        Exclusion Criteria:

          -  Pregnancy or nursing patients

          -  Patients who do not wish to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Hartley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Katherine Hartley</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>desmoid</keyword>
  <keyword>FES-PET</keyword>
  <keyword>aggressive fibromatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
    <mesh_term>Fibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

